Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of COVID-19-targeted non-pharmaceutical interventions on pediatric hospital admissions in North Italian hospitals, 2017 to 2022: a quasi-experimental study interrupted time-series analysis.
Maglietta G, Puntoni M, Caminiti C, Pession A, Lanari M, Caramelli F, Marchetti F, De Fanti A, Iughetti L, Biasucci G, Suppiej A, Miceli A, Ghizzi C, Vergine G, Aricò M, Stella M, Esposito S; Emilia-Romagna Paediatric COVID-19 network. Maglietta G, et al. Among authors: caminiti c. Front Public Health. 2024 Apr 18;12:1393677. doi: 10.3389/fpubh.2024.1393677. eCollection 2024. Front Public Health. 2024. PMID: 38699417 Free PMC article.
Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients.
Passalacqua R, Caminiti C, Campione F, Diodati F, Todeschini R, Bisagni G, Labianca R, Dalla Chiesa M, Bracci R, Aragona M, Artioli F, Cavanna L, Masina A, De Falco F, Marzocchini B, Iacono C, Contu A, Di Costanzo F, Bertetto O, Annunziata MA. Passalacqua R, et al. Among authors: caminiti c. J Clin Oncol. 2009 Apr 10;27(11):1794-9. doi: 10.1200/JCO.2007.15.0615. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273715 Clinical Trial.
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C. Passalacqua R, et al. Among authors: caminiti c. Cancer Immunol Immunother. 2010 Apr;59(4):553-61. doi: 10.1007/s00262-009-0773-9. Epub 2009 Sep 25. Cancer Immunol Immunother. 2010. PMID: 19779715 Free PMC article. Clinical Trial.
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Buti S, Lazzarelli S, Chiesa MD, Simonelli C, Re GL, Lheshi A, Simon S, Mattioli R, Caminiti C, Mazza G, Donini M, Passalacqua R; GOIRC (Italian Oncology Group for Clinical Research). Buti S, et al. Among authors: caminiti c. J Immunother. 2010 Sep;33(7):735-41. doi: 10.1097/CJI.0b013e3181eb8289. J Immunother. 2010. PMID: 20664353 Clinical Trial.
94 results